Drugs.com - Clinical Trials

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension

RADNOR, Pa., March 29, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea...

Apr 8, 2025 - 04:55
 0
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension
RADNOR, Pa., March 29, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea...
Read More

Tags:

Previous Article

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Next Article

Safe, Strong and Precise Magnetic Lifting

Related Posts

Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer

Gradalis Secures FDA Regenerative Medicine Advanced The...

Feb 9, 2025  0

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Salarius Pharmaceuticals Announces Patient Enrollment t...

Feb 9, 2025  0

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Tris Pharma Announces Positive Results from ALLEVIATE-1...

Feb 9, 2025  0